Key Developments: Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

87.74USD
1:42pm EDT
Price Change (% chg)

$-0.67 (-0.76%)
Prev Close
$88.41
Open
$88.15
Day's High
$88.15
Day's Low
$87.50
Volume
177,502
Avg. Vol
245,414
52-wk High
$91.65
52-wk Low
$71.00

Search Stocks

Latest Key Developments (Source: Significant Developments)

Novartis Alcon's Simbrinza approved in European Union to treat patients living with glaucoma
1:16am EDT 

Novartis AG:Says Alcon's Simbrinza approved in EU to treat patients living with glaucoma, chronic sight-threatening eye disease.Says launch of Simbrinza in the EU will start in UK in third quarter of 2014, followed by other European markets later in 2014 and in 2015.  Full Article

Novartis AG reaffirms FY 2014 outlook - Conference Call
Thursday, 17 Jul 2014 08:00am EDT 

Novartis AG:Reconfirms group outlook for FY 2014.Expects FY 2014 group net sales to grow low to mid single digits.Refines FY 2014 expectation for group core operating income growth to growing ahead of sales and growing mid to high single digit in constant currencies.Reported net sales of $57.920 billion and EBIT of $14.485 billion in FY 2013.FY 2014 revenue of $58.762 billion - Thomson Reuters I/B/E/S.  Full Article

Novartis AG submits application to FDA for meningitis B vaccine candidate Bexsero
Tuesday, 17 Jun 2014 08:00am EDT 

Novartis AG:Submission of Biologic License Application (BLA) to U.S. Food and Drug Administration (FDA) for marketing approval for use of Bexsero (Multicomponent Meningococcal Group B Vaccine [recombinant, adsorbed]).Says to help protect against invasive meningococcal disease caused by serogroup B (meningitis B) in adolescents and young adults from 10 years through 25 years of age.This submission initiates rolling submission process for Bexsero to the FDA, following the receipt of Breakthrough Therapy designation in April.  Full Article

Moody affirms all ratings of Novartis AG, outlook stable - Reuters
Thursday, 24 Apr 2014 06:52am EDT 

Novartis AG:Moody affirms all ratings of Novartis, outlook stable - Reuters.Affirmation of Novartis' rating follows analysis of rating implication of proposed four leg transaction announced by Novartis on April 22.This is regarding acquisition of GSK's oncology products, disposal of group's vaccines business (excluding the flu vaccines franchise) to GSK for, creation of consumer healthcare joint venture owned 36.5 pct by Novartis and sale of group's Animal Health business to Eli Lilly.Stable outlook assigned to current rating reflects Moody's expectation that Novartis to maintain financial policy going forward and that group's credit metrics to not drop materially below expectations for current rating pro-forma of the closing of transaction.  Full Article

Novartis AG confirms FY 2014 outlook
Thursday, 24 Apr 2014 02:43am EDT 

Novartis AG:Says FY 2014 outlook remains unchanged.Expects group net sales in FY 2014 to grow at low to mid-single digit rate (cc).Expects group core operating income to grow ahead of sales (cc) in FY 2014.FY 2013 net sales of $57.9 billion.FY 2013 core operating income of $14.5 billion.  Full Article

GlaxoSmithKline Consumer Healthcare Ltd announces GSK plc transaction with Novartis AG
Tuesday, 22 Apr 2014 06:00am EDT 

GlaxoSmithKline Consumer Healthcare Ltd:GSK Plc and Novartis AG have entered into an agreement to create consumer healthcare joint venture.To hold GSK's consumer healthcare business and Novartis OTC consumer healthcare business.JV will exclude GlaxoSmithKline Consumer Healthcare Ltd India, where GSK plc will continue to hold directly its interests in the listed entity.  Full Article

Novartis AG to divest Animal Health Division to Lilly for approximately $5.4 billion
Tuesday, 22 Apr 2014 01:00am EDT 

Novartis AG:To divest its Animal Health Division to Lilly for approximately $5.4 billion.This transaction is result of competitive process, which upon completion would create animal health business under Lilly's ownership and would optimize value of asset in interest of Novartis shareholders.Transaction with Lilly expected to close by end of first quarter of 2015.  Full Article

Novartis AG's OTC and GSK Consumer Healthcare to form joint venture
Tuesday, 22 Apr 2014 01:00am EDT 

Novartis AG:Says agreed with GSK to create consumer healthcare business through joint venture between Novartis OTC and GSK Consumer Healthcare.Upon completion, Novartis to own 36.5 pct share of joint venture and to have four of eleven seats on joint venture's Board.Novartis to have customary minority rights and exit rights at pre-defined, market-based pricing mechanism.  Full Article

Novartis AG to acquire GlaxoSmithKline plc oncology products; to divest Vaccines business to GSK, excluding flu business
Tuesday, 22 Apr 2014 01:00am EDT 

Novartis AG:Announces it has reached definitive agreement with GlaxoSmithKline plc (GSK) to exchange certain assets, building global leadership in key segments and focusing company's portfolio.Under agreement, Novartis would strengthen company's pharmaceuticals business by acquiring GSK oncology products, and would divest Vaccines (excluding flu) to them.Novartis has agreed to acquire GSK oncology products for $14.5 billion payment and up to $1.5 billion contingent on development milestone.Under terms of transaction, Novartis would have opt-in rights to GSK's current and future oncology R&D pipeline.Has agreed to divest its Vaccines business to GSK, excluding its flu business, for $7.1 billion plus royalties.Says $7.1 billion consists of $5.25 billion upfront and up to $1.8 billion in milestones.As part of value-maximization strategy in context of portfolio review, Novartis has initiated separate sales process for its flu business.  Full Article

France's competition authority investigates Roche Holding AG and Novartis AG in relation to eye disease treatments - Reuters
Wednesday, 9 Apr 2014 08:00pm EDT 

Novartis AG:France's competition authority is investigating Roche and Novartis on suspicion they were involved in anti-competitive practices in relation to eye disease treatments - Reuters.This is second time in as many months that Swiss drugmakers have faced regulatory scrutiny over treatments for wet age-related macular degeneration (AMD)- cause of blindness among elderly.Last month, prosecutors in Rome opened investigation into four executives at Swiss drugmakers on suspicion of fraud and manipulation of pharmaceutical market, according to judicial sources.Earlier in March, Italy's antitrust authority said Roche and Novartis colluded to try to stop cancer drug Avastin from being used to treat AMD and fined companies 182.5 million euros ($254.2 million).Regulator accused firms of striking alliance to prevent distribution of Roche's Avastin in favour of the more expensive drug Lucentis made by Novartis.  Full Article

Photo

Novartis says Alcon glaucoma treatment approved in EU

ZURICH - Swiss pharmaceutical group Novartis said the European Commission has approved its eyecare unit Alcon's Simbrinza treatment for glaucoma, a chronic, sight-threatening eye disease.

Search Stocks